SBFM Sunshine Biopharma Inc
Company Analysis
Latest News
🟢 Sunshine Biopharma is trading 8.18% up in pre-market with no clear company-specific catalyst identified
Sunshine Biopharma is trading at $3.02, up 8.18% in pre-market, with no clear company-specific catalyst identified. - The latest company press release located...
🟢 Sunshine Biopharma is trading 5% up; no clear catalyst identified
Sunshine Biopharma is trading 5.28% up at $2.79 on November 5, 2026, with no clear company-specific catalyst identified. - The broader market and biotech...
🟢 Sunshine Biopharma is trading 8.68% up in pre-market on November 5, 2026 with no clear catalyst
Sunshine Biopharma is trading at $2.88, up 8.68% in pre-market on November 5, 2026, with no definitive catalyst identified. - No new company-specific...
🟢 Sunshine Biopharma is trading 6% up in after-hours trading
Sunshine Biopharma is trading at $2.81, up 6.04% after hours on November 4, 2026, with no verified company-specific announcement explaining the move. - The...
🔴 Sunshine Biopharma is trading 5% down on November 4, 2026
Sunshine Biopharma is trading at $2.60, down 5.09%, with no independently corroborated company-specific announcement explaining the November 4 decline. - A...
Sunshine Biopharma Reports Phase 2 Progression-Free Survival Gain, Shares Surge
Sunshine Biopharma Inc. reported positive topline results from its Phase 2 trial of SBFM-PL4, an anti-cancer drug candidate. The study met its primary...
🟢 Sunshine Biopharma is trading 8.35% up in pre-market with no clear catalyst identified
Sunshine Biopharma is trading at $2.97, up 8.35% in pre-market, with the cause of the November 4, 2026 rise unclear. - No clear company-specific announcement...
🔴 Sunshine Biopharma is trading 6.6% down in pre-market
Sunshine Biopharma is trading 6.6% down at $2.57 in pre-market, compared with its November 2 close of $2.75; no clear new catalyst was identified. - Price...
🔴 Sunshine Biopharma is trading 6.1% down with no clear catalyst identified
On November 2, 2026, Sunshine Biopharma is trading 6.1% lower at $2.75, with no clear catalyst identified. - The latest prominent company news was an October...